Innovimmune Biotherapeutics Inc. is using structure-based drug design to develop small molecules that precisely modulate the activity of autoimmune targets that other companies are also targeting, but for which there are not yet marketed drugs.

The company is focusing its discovery efforts against proteins that could be targeted in a variety of inflammatory and autoimmune indications.